We announce the release of more than 20 new antibodies! For the first time we carry an IVD-certified, rabbit monoclonal ROS1 antibody (EP282), which can be used to improve treatment stratification of NSCLC patients. Furthermore we offer a new marker for BAP1 (C4), which differentiates mesothelioma from reactive mesothelial proliferation. Moreover with 4E-BP1 (EP352), 5T4 (EP347), FAP (SP325) and Napi2b (SP322) we cover interesting markers for several potentially therapeutic targets. Detailed information is provided in the following brochure: New arrivals 2017.

• Homepage brochure